- Evolocumab - a new era in the treatment of dyslipidemia2015 | First Faculty of Medicine
- Treating hypercholesterolaemia with evolocumab +12018 | First Faculty of Medicine
- Repatha - evolocumab, first in Europe registered inhibitors PCSK2015 | First Faculty of Medicine
- Evolocumab - novel options in the treatment of hyperlipidemia2016 | Faculty of Medicine in Hradec Králové
- Evolocumab: lowering of both the LDL cholesterol and cardiovascular risk2015 | First Faculty of Medicine
- Evolocumab - antibody against PCSK9 with a profound lipid-lowering effect2015 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 20140128Publication without faculty affiliation
- Několik postřehů ze studie FOURIER s evolocumabem2017 | First Faculty of Medicine
- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- Evolocumab přidaný ke statinu snižuje riziko kardiovaskulárních příhod2018 | First Faculty of Medicine
- Chronická zánětlivá demyelinizační polyneuropatie nabazující na léčbu evolocumabem2023 | First Faculty of Medicine
- Evolocumab and PROFICIO Project: Initial Results2015 | Third Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 20110109Publication without faculty affiliation
- Contemporary and modern treatment of hyperlipoproteinemia2016 | First Faculty of Medicine
- What have imaging studies with evolocumab yielded?2022 | First Faculty of Medicine
- Evolocumab významně snížil hladinu LDL cholesterolu u diabetiků 2. typu s dyslipidemií léčených maximální tolerovanou dávkou statinů2019 | First Faculty of Medicine
- Evolokumab for the treatment of familial hypercholesterolaemia2017 | Faculty of Medicine in Hradec Králové
- PCSK9 inhibitor evolocumab in the FOURIER outcomes trial2017 | First Faculty of Medicine
- Evolocumab for the treatment of familial hypercholesterolemia2017 | Faculty of Medicine in Hradec Králové
- Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Selected comments on the FOURIER study2017 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment 20120153Publication without faculty affiliation
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia2014 | First Faculty of Medicine
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease2017 | Second Faculty of Medicine
- Komentář ke studii2015 | First Faculty of Medicine
- Familial hypercholesterolemia2014 | First Faculty of Medicine
- Monoclonal antibodies in the treatment of dyslipidemia and cardiovascular risk lowering2016 | First Faculty of Medicine
- Present and future treatment of hyperlipoproteinemia and dyslipidemia in everyday practice2017 | First Faculty of Medicine
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial2016 | First Faculty of Medicine